Nyiro Gyula Orszagos Pszichiatriai Es Addiktologiai Intezet

The institute is conducting research focused on Parkinson's disease, migraine, and various epilepsy syndromes to test new treatments and improve long‑term safety profiles. Studies also target primary progressive multiple sclerosis with the aim of evaluating higher‑dose antibody therapy for slowing disability.

• Long‑term safety of novel oral agents in Parkinson’s disease
• Acute treatment efficacy for migraine attacks
• Adjunctive therapy for refractory focal‑onset epilepsy
• Disease‑modifying strategies in primary progressive multiple sclerosis
• Safety of investigational drugs in Dravet and Lennox‑Gastaut syndromes

Nyiro Gyula Orszagos Pszichiatriai Es Addiktologiai Intezet supports these investigations through its dedicated neurology unit.

Clinical work at the site includes trials for Major Depressive Disorder that explore novel adjunctive agents to reduce depressive symptoms. Research also addresses bipolar‑I mania by comparing new oral compounds with placebo to achieve faster mood stabilization.

• Evaluation of new antidepressant candidates in adult MDD
• Assessment of safety and tolerability of long‑term therapy for bipolar mania
• Comparison of rapid‑acting anxiolytics for seizure‑related agitation
• Investigation of novel mechanisms for mood episode control in bipolar disorder
• Open‑label extensions to monitor chronic use outcomes in psychiatric conditions

The Gyula Nyírő National Institute of Psychiatry and Addiction provides a multidisciplinary environment for advancing mental health research.